Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | GAA | P10253 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | METAP2 | P50579 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | PNLIP | P16233 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225897 | 0.85 | NPC1 (0.74) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL12189549 | 0.84 | NPC1 (0.72) | NPC1RAB9ALMNAGAAMETAP2 | |
| SCHEMBL5080078 | 0.84 | PNLIP (0.91) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL3949532 | 0.84 | KMT2A (0.78) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL4436642 | 0.83 | KCNK3 (0.77) | NPC1RAB9ALMNAGAAHPGD | |
| SCHEMBL4442096 | 0.83 | RAB9A (0.74) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL1825853 | 0.83 | NPC1 (0.70) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL3684485 | 0.83 | HPGD (0.79) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL29519361 | 0.83 | HPGD (0.79) | NPC1RAB9ALMNAGAAHTT | |
| SCHEMBL21993 | 0.83 | HPGD (1.00) | NPC1RAB9ALMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55053207-A | — | — | None | — | — | JP | disclosed |
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| EP-2951179-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | Merck Patent GmbH (DE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014117920-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014117920-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | WO | disclosed |
| US-20130310351-A1 | Treating Long QT Syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012054718-A2 | TREATING LONG QT SYNDROME | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
| JP-S5553207-A | WOOD PRESERVATIVE | YOSHITOMI PHARMACEUT IND LTD | 1980-04-18 | — | — | JP | disclosed |
| US-4105693-A | REACTING ALKYL 2-ALKYL BENZOATE WITH AN ANILINE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1978-08-08 | — | — | US | disclosed |
| US-3985804-A | Agricultural substituted 2-methylbenzanilide germicide | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
| US-3937840-A | COMPOSITIONS AND METHODS OF COMBATTING BACTERIA AND FUNGI USING 2-METHYLBENZANILIDE DERIVATIVES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310351-A1 | Treating Long QT Syndrome | TNNI3, TNNT2, TNNC1 | NPC1 1603/4885RAB9A 1007/4885LMNA 127/4885 |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | NPC1 3246/4885RAB9A 1024/4885LMNA 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.